An open-label single arm interventional phase 2 study to investigate outcome of individualized treatment based on pharmacogenomic profiling and ex vivo drug sensitivity testing of patient-derived organoids in patients with metastatic colorectal cancer

Colorectal cancer

Pre-screening: Number of patients from whom organoids and a full combined pharmacogenomic profiling were established and eligible for considering an MTBnominated treatment provided in the Main Study, Main study: Objective response rate (ORR) is a confirmed complete response (CR) or partial response (PR).  ORR in the total population.  ORR in each study drug cohort

Pre-screening: Number of patients from whom organoids and a full combined pharmacogenomic profile was established and eligible to have suggested:  An MTB-nominated treatment provided in the Main Study.  An MTB-nominated treatment considered as SOC.  An MTB-nominated treatment not considered as SOC and not provided in the Main Study.  No MTB-nominated treatment, Pre-screening:  Registered outcome of all systemic SOC oncological treatment; objective response (OR), PFS and DOR.  OS from start of firstline SOC chemotherapy and OS from start of each line of SOC treatment, Main study:  PFS, defined as the time from the first dose of the MTB-nominated treatment to the first documented disease progression or death due to any cause, whichever occurs first.  DOR, defined as the time from the first documented evidence of CR or PR until progressive disease (PD) or death due to any cause, whichever occurs first, in participants demonstrating CR or PR, Main study: OS, defined as the time from the first dose of MTB-nominated treatment to the date of death from any cause.  Classify and register adverse vents., Main study:  Assess ORR, DOR, PFS of MTB-nominated treatment and from the previous line of SOC treatment regimen in each patient.  Assess the number of patients who have a PFS of the MTB-nominated treatment which is >1.3 x PFS of the previous line of therapy., Main study: Assess ORR, DOR, PFS and of MTB-nominated treatment and form anticancer therapy in the next/later lines of SOC treatment in each patient, Main study: Patient-reported outcome measures

No related papers found yet.

Norway